| Tiffany Hughes, MA, CCC-SLP | |
|
980 S Arroyo Pkwy Ste 100, Pasadena, CA 91105-3924 | |
| (626) 799-7955 | |
| (626) 799-7957 |
| Full Name | Tiffany Hughes |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 980 S Arroyo Pkwy Ste 100, Pasadena, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124292107 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 19420 (California) | Primary |
| Provider Name | Expressive Connections Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477953792 PECOS PAC ID: 4183002108 Enrollment ID: O20220603001336 |
News Archive
Lawmakers in Connecticut are considering re-introducing a bill for a public option for health insurance that died last year in the legislature. Similarly in California, state lawmakers are pushing a single-payer bill that died in the legislature last year.
Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.
A new study has revealed that the immune system plays a crucial and previously unidentified role in Alzheimer's disease.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany Hughes, MA, CCC-SLP 2143 Windsor Ave, Apt C, Altadena, CA 91001-5378 Ph: () - | Tiffany Hughes, MA, CCC-SLP 980 S Arroyo Pkwy Ste 100, Pasadena, CA 91105-3924 Ph: (626) 799-7955 |
News Archive
Lawmakers in Connecticut are considering re-introducing a bill for a public option for health insurance that died last year in the legislature. Similarly in California, state lawmakers are pushing a single-payer bill that died in the legislature last year.
Researchers from Case Western Reserve University School of Medicine and the Dana-Farber Cancer Institute have made a fundamental discovery relevant to the understanding and treatment of heart failure - a leading cause of death worldwide. The team discovered a new molecular pathway responsible for causing heart failure and showed that a first-in-class prototype drug, JQ1, blocks this pathway to protect the heart from damage.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.
A new study has revealed that the immune system plays a crucial and previously unidentified role in Alzheimer's disease.
› Verified 4 days ago
Kay Ann Dabler, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 S Fair Oaks Ave, Suite 401, Pasadena, CA 91105 Phone: 626-744-0411 Fax: 626-744-0431 | |
Miss Emily James, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 620 N Lake Ave, Pasadena, CA 91101 Phone: 626-793-7350 Fax: 626-793-7341 | |
Ms. Stephanie Mu, MS, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 980 S Arroyo Pkwy Ste 100, Pasadena, CA 91105 Phone: 626-799-7955 | |
Aikaterini Kalyvioti, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 350 E California Blvd Apt 108, Pasadena, CA 91106 Phone: 626-381-8292 | |
Erin Burdett, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 620 N Lake Ave, Pasadena, CA 91101 Phone: 626-793-7350 | |
Lauren M Harman, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1561 N Oxford Ave, Pasadena, CA 91104 Phone: 619-846-2019 | |
Shanee Fulton, M.S. Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 351 S. Hudson Ave, Pasadena, CA 91109 Phone: 626-396-3600 |